The oncofetal antigen 5T4 is a cell surface glycoprotein overexpressed in many solid tumors, while its expression in normal tissues is limited, making it an attractive target for cancer therapies. Its association with tumor progression and poor prognosis further supports its therapeutic potential.

Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and the innate immunity signaling pathway in physiology or medicine, as well as the identification of leukemia stem cells and ghrelin, the so-called hunger hormone.

Glioblastoma, the most aggressive and lethal form of brain cancer in adults, has long evaded effective treatment due to its resistance to standard therapies, including surgical resection, radiation, chemotherapy and targeted agents.

A recently published study in the Journal for Immunotherapy of Cancer presents a novel bispecific antibody-cytokine fusion protein that effectively enhances antitumor immunity.

Osteosarcoma, the most common bone cancer in children and young adults, has poor outcomes after relapse with only ~18% 5-year survival, underscoring the urgent need for new therapies. Researchers from New York Medical College and colleagues have now demonstrated a new strategy to improve the efficacy of natural killer (NK) cell-based immunotherapy for osteosarcoma.

Immuto Scientific Inc. has closed an $8 million seed 2 financing round and entered into a drug discovery collaboration with Daiichi Sankyo Co. Ltd. Immuto applies its target discovery platform and structural epitope‑mapping engine to identify disease‑specific surface protein conformations.

Metastatic and relapsed osteosarcoma remains challenging to treat despite the introduction of advanced surgical techniques, intensified chemotherapy and targeted therapies. Adoptive immunotherapies such as CAR T cells, despite being in nascent stages, are considered a potential option for treating aggressive solid tumors such as osteosarcoma.

When Robert Kennedy Jr. announced the cancellation of 22 projects related to mRNA vaccines and the end of new investments in that technology, the U.S. Secretary of Health only mentioned their use against respiratory viruses, without referring to other applications. The vaccines whose safety and effectiveness Kennedy is questioning are based on the same molecular principles as cancer vaccines under development. “Continued investment in mRNA technology is essential to fully realize its potential in oncology and ensure that promising strategies like neoantigen-based vaccines reach clinical application.” Kazuhiro Kakimi, professor at the Department of Immunology at Kindai University Faculty of Medicine, told BioWorld.

Researchers from Xi’an Jiaotong University and Southern University of Science and Technology have conducted a comprehensive preclinical study to evaluate the efficacy and safety of a second-generation CAR T therapy targeting trophoblast cell-surface antigen 2 (TROP2) for the treatment of triple-negative breast cancer.